288-14-2
Chemical Structure
Isoxazole
- CAS No.: 288-14-2
- Formula:C3H3NO
- Molecular Weight:69.06
IUPAC Name: isoxazole
InChIKey: CTAPFRYPJLPFDF-UHFFFAOYSA-N
SMILES: C1=CON=C1
Biological Activity: Isoxazole is a member of the five-membered heterocycle drug scaffold. Isoxazole has been used as a BET bromodomain inhibitor and can improve β-cell function in a diabetic mouse model. Isoxazole and its derivatives exhibit broad biological activities (such as antimicrobial, antibacterial, antifungal, antiviral, anticancer, anti-inflammatory, immunomodulatory, analgesic, anti-tuberculosis, and anti-diabetic effects). For example, the bicyclic Isoxazole can act as an HSP90 inhibitor, and the tricyclic Isoxazole is promising as a selective multidrug resistance protein (MRP1) inhibitor[1][2][3][4][5].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Isoxazole | 99.98% | Isoxazole is a member of the five-membered heterocycle drug scaffold. Isoxazole has been used as a BET bromodomain inhibitor and can improve β-cell function in a diabetic mouse model. Isoxazole and its derivatives exhibit broad biological activities (such as antimicrobial, antibacterial, antifungal, antiviral, anticancer, anti-inflammatory, immunomodulatory, analgesic, anti-tuberculosis, and anti-diabetic effects). For example, the bicyclic Isoxazole can act as an HSP90 inhibitor, and the tricyclic Isoxazole is promising as a selective multidrug resistance protein (MRP1) inhibitor. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Isoxazole (Standard) | ≥98% | Amfenac (Sodium Hydrate) (Standard) is the analytical standard of Amfenac (Sodium Hydrate). This product is intended for research and analytical applications. Amfenac Sodium Hydrate is a COX-2 inhibitor. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Zhu J, et al. The recent progress of isoxazole in medicinal chemistry. Bioorg Med Chem. 2018 Jul 23;26(12):3065-3075. [Content Brief]
- [2]. Sysak A, et al. Isoxazole ring as a useful scaffold in a search for new therapeutic agents. Eur J Med Chem. 2017 Sep 8;137:292-309. [Content Brief]
- [3]. Norman BH, et al. Tricyclic isoxazoles are novel inhibitors of the multidrug resistance protein (MRP1)[J]. Bioorg Med Chem Lett. 2002 Mar 25;12(6):883-6. [Content Brief]
- [4]. Agrawal N, Mishra P. The synthetic and therapeutic expedition of isoxazole and its analogs[J]. Med Chem Res. 2018;27(5):1309-1344. [Content Brief]
- [5]. Kalwat MA, et al. Isoxazole Alters Metabolites and Gene Expression, Decreasing Proliferation and Promoting a Neuroendocrine Phenotype in β-Cells. ACS Chem Biol. 2016 Apr 15;11(4):1128-36. [Content Brief]
